790.74
-5.60 (-0.70%)
| Previous Close | 796.34 |
| Open | 803.01 |
| Volume | 653,505 |
| Avg. Volume (3M) | 743,925 |
| Market Cap | 81,410,629,632 |
| Price / Earnings (TTM) | 19.55 |
| Price / Earnings (Forward) | 14.51 |
| Price / Sales | 5.53 |
| Price / Book | 2.60 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2026 |
| TTM Dividend Yield | 0.47% |
| Profit Margin | 31.94% |
| Operating Margin (TTM) | 19.94% |
| Diluted EPS (TTM) | 39.36 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 12.00% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | 3.95 B |
| Levered Free Cash Flow (TTM) | 2.08 B |
| Return on Assets (TTM) | 6.91% |
| Return on Equity (TTM) | 15.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Regeneron Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -4.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Relative Valuation | -5.0 |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 0.50 |
Select this tab to load the latest available analysis.
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.89% |
| % Held by Institutions | 91.98% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MURPHY ANDREW J | - | 765.74 | -17,000 | -12,907,710 |
| Aggregate Net Quantity | -17,000 | |||
| Aggregate Net Value ($) | -12,907,710 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 765.74 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MURPHY ANDREW J | Officer | 14 Oct 2026 | Automatic sell (-) | 4,147 | 778.36 | 3,227,859 |
| MURPHY ANDREW J | Officer | 13 Oct 2026 | Automatic sell (-) | 12,853 | 753.12 | 9,679,851 |
| MURPHY ANDREW J | Officer | 13 Oct 2026 | Option execute | 17,000 | - | - |
| TTM Dividend Yield | 0.47% |
| 1Y Average Dividend Yield | 0.46% |
| Payout Ratio | 2.24% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 18 Aug 2026 | - | 31 Aug 2026 | 0.94 Cash |
| 20 May 2026 | - | 04 Jun 2026 | 0.94 Cash |
| 20 Feb 2026 | - | 05 Mar 2026 | 0.94 Cash |
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 Cash |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Cash |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Cash |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 2.82 | 3 | 0.36 |
| 2025 | 3.52 | 4 | 0.46 |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |